Application of miR-495-3p in preparation of medicine for treating spinal cord injury

MiR-495-3p reduces Bax expression, increases Bcl-2/Bax ratio, inhibits the apoptosis of spinal cord neuron cells, solves the apoptosis problem in the treatment of spinal cord injury in the prior art, and provides new treatment methods and pathways.

CN118903178AInactive Publication Date: 2024-11-08LUOYANG ORTHOPEDIC TRAUMATOLOGICAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410959473.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment methods for spinal cord injury have failed to effectively inhibit the apoptosis of neuronal cells, resulting in irreversible damage to spinal cord function, and lack of effective treatment strategies.

Method used

Through the application of miR-495-3p, the expression of Bax in spinal cord cells is reduced, the Bcl-2/Bax ratio is increased, thereby inhibiting the apoptosis of spinal cord neuronal cells, providing a new drug for treating spinal cord injury.

Benefits of technology

It significantly inhibits the apoptosis of neuronal cells after spinal cord injury, provides new methods and pathways for the treatment of spinal cord injury, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903178A_ABST
    Figure CN118903178A_ABST
Patent Text Reader

Abstract

The invention discloses application of miR-495-3p in preparation of a medicine for treating spinal cord injury, and belongs to the technical field of biological medicine. The nucleotide sequence of the miR-495-3p is 5 '-AAACAAACAUGGUGCACUUCUU-3', and the nucleotide sequence of the miR-495-3p is shown in the description. Experiments prove that by improving the expression level of miR-495-3p, the expression level of Bax in rat spinal cord neuronal cells can be reduced, and the Bcl-2 / Bax ratio is up-regulated, so that apoptosis of the neuronal cells after spinal cord injury is inhibited; the miR-495-3p can be used for preparing the medicine for treating the spinal cord injury, or other key proteins on a miR-495-3p / Bcl-2 / Bax signal channel are used as treatment targets to carry out precise treatment on the spinal cord injury. The invention provides a new pathway and method for treatment of spinal cord injury, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to application of miR-495-3p in preparing medicine for treating spinal cord injury. Background Art

[0002] Spinal cord injury is a central nervous system disease with high disability and mortality, which is serious and has an increasing incidence. It is reported that the prevalence of traumatic spinal cord injury is 236 / 1 million to 4187 / 1 million. Severe secondary injuries after traumatic spinal cord injury can lead to irreversible damage to neurological functions such as movement and sensation, resulting in loss of labor, limb paralysis, incontinence, loss of self-care ability in daily life, and seriously affecting the quality of life of patients. At present, the commonly used clinical treatments for spinal cord injury include surgery, drugs, hyperbaric oxygen and physical therapy, but none of them have achieved satisfactory results. Therefore, new treatment strategies for spinal cord injury are urgently needed.

[0003] Neuronal cell apoptosis is an important pathological mechanism causing secondary spinal cord injury. After spinal cord injury, the axonal damage leads to interruption of nutrient supply, resulting in neuronal cell apoptosis. A large number of neuronal cells undergo apoptosis, causing serious and irreversible damage to the spinal cord. Therefore, inhibiting apoptosis can alleviate secondary spinal cord injury and facilitate the recovery and reconstruction of spinal cord function after spinal cord injury. So far, the exact molecular mechanism of apoptosis is still unclear, but apoptosis involves the activation of a series of intracytoplasmic apoptotic proteins and the cleavage of substrates. B-cell lymphoma-2 (Bcl-2) is an anti-apoptotic protein, and Bcl-2-associated X protein (Bax) is a pro-apoptotic protein. Bcl-2 and Bax can form homodimers or heterodimers through BH1 and BH2. Bcl-2 can inhibit apoptosis only by forming heterodimers with Bax, and Bcl-2 / Bax heterodimers must be greater than Bcl-2 / Bcl-2 homodimers and Bax / Bax homodimers to inhibit cell apoptosis. Therefore, the ratio of Bcl-2 / Bax in cells directly determines whether the cells will undergo apoptosis.

[0004] MicroRNA (miRNA) is a non-coding RNA that interacts with genes through its 3' untranslated region, inhibits or degrades its target genes through RNA-induced silencing complexes, inhibits protein synthesis, and regulates a variety of biological processes. Existing studies have shown that after spinal cord injury, a variety of miRNAs are differentially expressed, suggesting that miRNAs are associated with neuronal apoptosis after spinal cord injury. Therefore, it is urgent to provide a method for regulating the expression of miRNAs that regulate the apoptosis factor Bax, targeting the corresponding apoptotic genes and signaling pathways to achieve an anti-apoptotic effect. Summary of the invention

[0005] The purpose of the present invention is to provide the use of miR-495-3p in the preparation of a drug for treating spinal cord injury to solve the problems existing in the above-mentioned prior art. miR-495-3p and its mimics can reduce the expression of Bax in spinal cord cells, thereby reducing the apoptosis rate of spinal cord neuronal cells.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides application of miR-495-3p in preparing medicine for treating spinal cord injury.

[0008] The present invention also provides the use of miR-495-3p in preparing a medicine for inhibiting neuronal cell apoptosis after spinal cord injury.

[0009] The present invention also provides the use of miR-495-3p in preparing a B-cell lymphoma-2-related X protein regulator, wherein the miR-495-3p downregulates the expression level of the B-cell lymphoma-related X protein.

[0010] Preferably, the nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.

[0011] The present invention also provides a medicine for treating spinal cord injury, comprising miR-495-3p.

[0012] The present invention also provides a drug for inhibiting neuronal cell apoptosis after spinal cord injury, comprising miR-495-3p.

[0013] Preferably, the nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.

[0014] Preferably, a pharmaceutically acceptable excipient is also included.

[0015] The present invention also provides a B-cell lymphoma-related X protein regulator, comprising miR-495-3p; the miR-495-3p downregulates the expression level of B-cell lymphoma-related X protein.

[0016] Preferably, the nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.

[0017] The present invention discloses the following technical effects:

[0018] The present invention provides the use of microRNA miR-495-3p in the preparation of drugs for treating spinal cord injury. The experiments of the present invention show that increasing the expression level of miR-495-3p can reduce the expression level of Bax in rat spinal cord neuronal cells and upregulate the Bcl-2 / Bax ratio, thereby significantly inhibiting the apoptosis of neuronal cells after spinal cord injury; miR-495-3p can be used to prepare drugs for treating spinal cord injury, or other key proteins in the miR-495-3p / Bcl-2 / Bax signaling pathway can be used as therapeutic targets to accurately treat spinal cord injury. The present invention provides a new pathway and method for the treatment of spinal cord injury, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1 Figure 2 is the effective binding site map of miR-495-3p and Bax; Bax-WT, Bax wild type; Bax-MT, Bax mutant;

[0021] Figure 2 The results of Western Blot detection of Bax protein expression in rat spinal cord tissue; 1 is the normal control group; 2 is the model group; GAPDH, glyceraldehyde phosphate dehydrogenase;

[0022] Figure 3 Statistical diagram of Bax expression level in spinal cord tissue of rats in each group; n = 3; * means P < 0.05;

[0023] Figure 4 The fluorescence statistics of rat spinal cord cell apoptosis detected by flow cytometry; A is the normal control group; B is the model group; Q, quadrant; B1-A::FITC-A, annexin B1::fluorescein isothiocyanate-annexin V; B3-A::PI_PE-A, annexin B3::propidium iodide_phosphatidylethanolamine-annexin V;

[0024] Figure 5 The statistical graph of apoptosis rate of spinal cord cells in each group of rats;

[0025] Figure 6 Statistical diagram of the relative expression of miR-495-3p in rat spinal cord tissue 3 days after modeling; * means P<0.05;

[0026] Figure 7The statistical diagram of the dual luciferase reporter gene experiment verifying the regulation of Bax expression by miR-495-3p; miR-495-3p-mimics, miR-495-3p mimics; Bax 3'-UTRWT, Bax 3' untranslated region wild type; Bax 3'-UTR MT, Bax 3' untranslated region mutant; *P<0.05;

[0027] Figure 8 This is a shape observation diagram of rat spinal cord neurons cultured for 48 hours; the magnification is 200×, and the scale bar in the figure is 50μm;

[0028] Fig. 9 These are observations of immunofluorescence staining of β-ⅢTubulin, a marker protein of neuronal dendrites; A is DAPI nuclear staining; B is immunofluorescence β-ⅢTubulin antibody staining; C is a composite image; the magnification is 200×, and the scale bar in the figure is 50μm;

[0029] Fig.10 The Western Blot test results of Bax protein expression in the spinal cord tissue of rats in each group; 1 is the normal control group; 2 is the model group; 3 is the miR-495-3p mimic group; 4 is the miR-495-3p inhibitor group; Actin, actin;

[0030] Fig.11 Statistical graph of Bax expression levels in spinal cord neurons of rats in each group; miR-495-3p-mimics, miR-495-3p mimics; miR-495-3p inhibitor, miR-495-3p inhibitor; n=3; **P<0.01;

[0031] Fig.12 The fluorescence statistical diagram of spinal cord cell apoptosis in each group of rats detected by flow cytometry; A is the normal control group; B is the model group; C is the miR-495-3p mimic group; D is the miR-495-3p inhibitor group; the horizontal and vertical axes are Figure 4 have the same meaning;

[0032] Fig.13 Statistical graph of the apoptosis rate of spinal cord cells in each group of rats affected by miR-495-3p; miR-495-3p-mimics, miR-495-3p mimics; miR-495-3p inhibitor, miR-495-3p inhibitor; n=3; **P<0.01. DETAILED DESCRIPTION

[0033] The various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and implementation schemes of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing specific embodiments and are not used to limit the present invention. Additionally, for the numerical ranges in the present invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any intermediate value within any stated value or stated range, as well as each smaller range between any other stated value or intermediate value within the stated range, is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0035] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention pertains. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the said documents. In case of conflict with any incorporated document, the content of this specification shall prevail.

[0036] Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific embodiments of the present invention specification, which are obvious to those skilled in the art. Other embodiments obtained from the present invention specification are also obvious to those skilled in the art. The present invention specification and examples are only exemplary.

[0037] Regarding "comprising", "including", "having", "containing", etc. used herein, they are all open-ended terms, meaning including but not limited to.

[0038] Example 1

[0039] 1. Materials and Methods

[0040] 1.1 Materials

[0041] 1.1.1 Experimental Animals

[0042] 20 SPF-grade SD rats (animal license number: SCXK(Yu)2019 - 0002), male, weighing 200 - 240 g, were provided by the Henan Experimental Animal Center. The breeding environment temperature of the animals was 20 - 24 °C, the humidity was 50% - 70%, with a 12-hour light-dark cycle, and the environmental noise was <50 dB.

[0043] Four SPF-grade SD rats at 3 days old (animal license number: SCXK(Yu)2019-0002), half male and half female, were provided by the Henan Experimental Animal Center.

[0044] 1.1.2 Drugs and reagents

[0045] The following drugs were purchased from Sinopharm Chemical Reagent Co., Ltd.: chloroform (product number 10006818); absolute ethanol (product number 10009218); isopropanol (product number 80109218).

[0046] The following reagents were purchased from Wuhan Sevier Biotechnology Co., Ltd.: RNA extraction solution (product number G3013); dye method SYBR Green qPCR premix (2×, without ROX) (product number G3320); RT First Strand cDNA Synthesis Kit (product number G3330); RIPA lysis buffer (product number G2002); BCA protein quantification detection kit (product number G2026); phosphorylated protease inhibitor (product number G2007); SDS-PAGE gel preparation kit (product number G2003).

[0047] 1.1.3 Instruments

[0048] Fluorescence quantitative PCR instrument (Bio-rad, USA, model CFX); ultra-micro spectrophotometer (Thermo, USA, model NanoDrop2000); desktop high-speed refrigerated microcentrifuge (DragonLab, USA, model D3024R); digital display pendulum shaker (Servicebio, USA, model DS-S100); vertical electrophoresis instrument (Servicebio, USA, model SVE-2); ultrasonic cell disruptor (Ningbo Xinzhi Biology, model JY92-11N); ultra-micro nucleic acid and protein concentration detector (Thermo Fisher, USA, model nanodropone); grayscale analysis software (Alpha Innotech, Australia, alphaEaseFC); image analysis software (Adobe, USA, model Adobe PhotoShop); chemiluminescence instrument (Shanghai Qinxiang Scientific Instrument Co., Ltd., batch number 6100).

[0049] 1.2 Methods

[0050] 1.2.1 Animal modeling

[0051] Twenty SD rats were randomly divided into a normal control group and a model group, with 10 rats in each group. The model group animals were intraperitoneally anesthetized with 3% sodium pentobarbital (40 mg / kg), and then the spinal cord hemisection method at the T9-10 segment was used to make a rat model of spinal cord injury (SCI). The wound was sutured and 20 U / kg of sodium penicillin was injected intramuscularly to prevent infection. After the animals woke up from anesthesia, they immediately showed tail wagging, convulsions of both lower limbs, or urinary incontinence. Three days after the operation, 8 rats survived in the model group, and all rats in the normal control group survived. The degree of muscle spasm was judged and recorded according to the BBB scoring method to determine that the model was successful.

[0052] 1.2.2 Analysis of differentially expressed genes between normal control group rats and model group rats

[0053] The present invention performed differentially expressed gene profile analysis on normal control group rats and model group rats, and the method was as follows:

[0054] Spinal cord tissues of rats in the model group and the normal control group were collected, and total RNA was extracted by Trizol method, and the total RNA was quantified and quality tested. The samples were prepared by single-round cRNA amplification and biotin labeling, and then used for chip hybridization; the chip used the HG-u133Plus 2.0 gene expression profile chip of Affymetrix Company, USA, and one chip was tested for each sample, for a total of 6 chips. Fluidics Station 450 was used for elution and staining, and then the chip was scanned by Scanner3000; the chip image was analyzed by GeneChip Operating software (GCOS1.4) analysis software, and the image signal was converted into a digital signal, and then the dChip software was used for correction and normalization. Finally, the differentially expressed genes were determined based on the standard of 1.5 times difference.

[0055] 1.2.3 Screening of differentially expressed miRNAs in the serum of normal control group rats and model group rats

[0056] The microarray method was used to detect differentially expressed miRNAs in the serum extracted from the model group and the normal control group. According to the Agilent miRNA Microarray Systemwith miRNA Complete Labeling and Hyb Kit protocol (Agilent Technology), 1881 rat miRNA samples were targeted for labeling and microarray hybridization. Three samples were repeated in each group. All differentially expressed miRNAs with a fold change value (FC) ≥ 1.5 and a difference of P ≤ 0.05 between the two groups were collected to establish a differentially expressed miRNA library.

[0057] 1.2.4 Bioinformatics query on the regulatory relationship between the above-screened apoptotic factors and the screened miRNAs

[0058] The bioinformatics websites Targetscan (https: / / www.targetscan.org / vert_80 / ) and miRWalk (http: / / 129.206.7.150 / ) databases were used to predict whether there was a regulatory relationship between the above-screened apoptotic factors and the screened miRNAs.

[0059] 1.2.5 Western blot detection of the above-identified target apoptotic factor Bax content in spinal cord tissue

[0060] Rats were fully anesthetized and killed by cervical dislocation. A portion of spinal cord tissue was taken from the surgical site, weighed, and added with 9 times the volume of phosphate buffered saline (PBS) and homogenized with a homogenizer. Centrifuged at 3000r / min for 20min, and the supernatant was collected and stored at -80℃. The protein concentration was measured by 2,2'-biquinoline-4,4'-dicarboxylic acid (BCA) method. An appropriate amount of protein was taken according to the protein concentration and loaded on 5× sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) for electrophoresis. After transfer, the membrane was blocked with 0.1% Tween-20 (Tween-20) in Tris-HCl buffered saline (TBST) containing 70 g / L skim milk powder on a shaker for 2 h. After sufficient rinsing with 1× TBST (5 min×3 times), rabbit anti-mouse Bax polyclonal antibody was added as the primary antibody (dilution of 1:1000) and shaken at 4°C overnight. After sufficient rinsing, goat anti-rabbit polyclonal antibody was added as the secondary antibody (dilution of 1:1000) and incubated on a shaker at room temperature for 2 h. After sufficient rinsing, the membrane was developed by chemiluminescence. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal reference, and the images were analyzed using Image-ProPlus6.0 software. The Bax / GAPDH value was used to represent the relative expression level of the target protein.

[0061] 1.2.6 Detection of spinal cord cell apoptosis by flow cytometry

[0062] Spinal cord tissues of rats in the normal control group and model group were taken respectively, weighed, added with pre-cooled distilled water, homogenized with a homogenizer, digested with trypsin and collected spinal cord cells. 1 mL of 1× Annexin V binding buffer was added, centrifuged at 800 r / min for 5 min, the supernatant was discarded, and the cells were resuspended with 200 μL binding buffer; 10 μL of Annexin V-fluorescein isothiocyanate (Annexin V-FITC) (5 mg / L) and 5 μL of propidium iodide (PI) were added, mixed and incubated at 37 ° C in a dark environment for 30 min. Flow cytometry was used to detect spinal cord cell apoptosis.

[0063] 1.2.7 Verification of differential expression of the above-screened target miRNAs in spinal cord tissue between the model group and the normal control group

[0064] The total RNA in the spinal cord tissue of each group was extracted using Trizol reagent, dissolved in ultrapure water (without RNase and DNase), and the concentration and purity were tested. The relative expression levels of the above-screened miRNAs were detected using the Taqman microRNART Kit and the housekeeping gene U6 as an internal reference.

[0065] First, total RNA was reverse transcribed into cDNA, and SYBR Green PCRMasterMix was used as a nucleic acid dye to prepare the reaction system: 1 μL cDNA, 2 μL upstream primer (5 μmol / L), 2 μL downstream primer (5 μmol / L), 10 μL SYBR Green PCRMasterMix, and ddH2O was added to 20 μL. Amplification was performed on an ABI Stepone Plus real-time fluorescence quantitative PCR instrument, and the reaction conditions were: 95°C, 10 min; 40 PCR cycles (95°C, 10 seconds; 60°C, 60 seconds); the cycle threshold (Ct) was recorded, and 2 -△△Ct Methods, to compare expression differences among sample groups.

[0066] The target miRNA screened was miR-495-3p, with the sequence 5'-AAACAAACAUGGUGCACUUCUU-3' (SEQ ID NO. 2).

[0067] 1.2.8 Dual luciferase reporter gene experiment verifies the regulatory relationship between miR-495-3p and Bax

[0068] The miRNA target gene prediction website RNAhybrid (https: / / bibiserv.cebitec.uni-bielefeld.de / rnahybrid / ) was used to predict the binding sites of miR-495-3p and Bax. Figure 1 shown.

[0069] Mutation sequences and target sequences were designed according to the binding sites, and restriction sites were added. The target fragments Bax-3' untranslated region wild type (3'-UTR WT) and mutant (3'-UTR MT) were synthesized by PCR and cloned into the pmirGLO vector. The miR-495-3p mimics (mimics, which are artificially synthesized miR-495-3p sequences) were co-transfected with the pmirGLO-Bax-WT / MT recombinant plasmids in 293T cells. The negative control was co-transfected with the miR-495-3p empty vector (scramble) and the pmirGLO-Bax-WT / MT recombinant plasmid. After the transfection process was completed, the cells were cultured at 37°C and 5% CO2 for 48 hours, and 1 mL of conventional DMEM medium containing 10% fetal bovine serum (FBS) and no antibiotics was replaced, and the cells were lysed for another 48 hours. 5 μL of cell lysate was taken from each group, and the relative fluorescence intensity was detected according to the operating instructions of the luciferase activity detection kit (Promage). The Renilla fluorescence value was used as the internal reference, and the fluorescence intensity of each group was divided by the internal reference as the relative fluorescence intensity of each group. Observe whether the fluorescence intensity of the mutant group is higher than that of the wild-type group. It is confirmed that miR-495-3p can directly regulate Bax expression.

[0070] The sequences of the wild-type (3'-UTRWT) and mutant (3'-UTRMT) of the target fragment Bax-3' untranslated region are:

[0071] Bax-WT: 5'-AGGAGUUUCGCCAUGUUGAGAG-3' (SEQ ID NO. 1);

[0072] Bax-MT: 5'-AGGAGUUUCGGGUACAAGAGAG-3' (SEQ ID NO. 3).

[0073] 1.2.9 Culture and identification of spinal cord neurons

[0074] Newborn rats at 3 days old were taken, soaked in 75% ethanol, dissected on ice, and the spinal cord was separated in PBS in an ice bath, washed 2-3 times with PBS, cut into pieces, and digested with 0.25% trypsin (Trypsin) + 0.1% type I collagenase in a 37°C water bath with shaking for 30 minutes. The centrifuge tube was taken out every 10 minutes, the tissue was gently blown, and the digestion was terminated with culture medium containing fetal bovine serum, and passed through a 100μm filter, the filtrate was collected, and centrifuged at 300g for 5 minutes. The precipitate was resuspended with complete culture medium and spread in a bottle.

[0075] When the cells grow to the logarithmic phase, take 3 glass slides and place them in a 24-well plate. Add 1 mL of culture medium to each well and add 2×10 cells. 4 / well, and place in an incubator overnight. After the cells crawled, aspirate the culture medium, wash once with PBS, and add 4% paraformaldehyde (PFA) to fix at 4℃ for 30min. Wash 3 times with PBS, 5min each time. Remove the moisture from the slide, take 50μL of membrane blocking solution and drop it on the waterproof film, cover the side of the slide with cells for 2h to block the membrane. 50 μL of primary antibody (rabbit anti-mouse IgG, primary antibody: PBS = 1:1000) was applied on a waterproof film (in a wet box), and the side of the slide with cells was covered. The slide was placed at 4°C for overnight incubation. After the incubation, the slide was washed with PBS 3 times, 5 min each time. 50 μL of secondary antibody (coupled goat anti-rabbit IgG, secondary antibody: PBS = 1:500) was applied on a waterproof film (in a wet box), and the side of the slide with cells was covered. After incubation at room temperature and away from light for 2 hours, the slide was washed with PBS 3 times, 5 min each time, and stained with 4',6-diamidino-2-phenylindole (DAPI) (DAPI: PBS = 1:1000) for 5 min, and then washed with PBS 3 times, 5 min each time. Then 1 drop of anti-fluorescence quenching mounting medium (Fluoromount-G) was dropped on each slide, and the side with cells was covered for embedding. Immunofluorescence was used to identify specific proteins.

[0076] 1.2.10 Effect of miR-495-3p on Bax expression in spinal cord cells

[0077] The spinal cord neuron cells of the model group rats and the normal control group rats were cultured according to the method in 1.2.9, cultured to the logarithmic growth phase, and divided into the normal control group: the spinal cord neuron cells of the normal control group rats were added with ordinary culture medium, the model group: the spinal cord neuron cells of the model group rats were added with ordinary culture medium, the miR-495-3p mimics group: the spinal cord neuron cells of the model group rats were added with miR-495-3p mimics 30 μM in the culture medium, the miR-495-3p inhibitor group: the spinal cord neuron cells of the model group rats were added with miR-495-3p inhibitor 50 μM in the culture medium, and each group was repeated 3 wells; the miR-495-3p inhibitor is a mature miRNA complementary single strand designed with methoxy modification, and its sequence is 5'-AAGUGCACCAUGUUUGU-3' (SEQ ID NO.4). After 2 days, the supernatant was taken and the total protein was extracted. After quantification according to the BCA kit method, SDS-PAGE electrophoresis was performed as in 1.2.2 to analyze the signal grayscale of the bands.

[0078] 1.2.11 Effect of miR-495-3p on the expression level of apoptotic factors in spinal cord cells of rats with spinal cord injury

[0079] Take the cell supernatant of each group cultured in 1.2.10, and detect it according to the operating instructions of the ELISA kit to determine the content of Bcl-2 and Bax in the spinal cord cells of each group, and compare the ratio of Bcl-2 / Bax.

[0080] 1.2.12 Effect of miR-495-3p on apoptosis of spinal cord neurons in rats with spinal cord injury

[0081] Divide the cells into groups as in 1.2.10 and perform the following experiment: Digest with trypsin and then wash once with PBS. Suspend the cells with 1 mL of Binding Buffer and centrifuge at 300 g for 10 min. Discard the supernatant. Resuspend the cells with 1 mL of Binding Buffer to a cell density of 1×10 6 Add 100 μL of cells (1×10 5 Then add 5 μL Annexin V-FITC to the tube. Mix gently at room temperature, away from light, for 10 min. Then add 5 μL PI, incubate at room temperature, away from light, for 5 min. Finally, add PBS to 500 μL and mix gently. Detect by flow cytometry within 1 hour. Observe the apoptosis of neuronal cells and calculate the apoptosis rate.

[0082] 1.3 Statistical methods

[0083] The relevant data were entered into Excel, and SPSS25.0 statistical software was used for statistical analysis. The measurement data were expressed as (x±s), and the comparison between multiple groups was performed by one-way analysis of variance. The least significant difference (LSD) test was used for the comparison between two groups, and the test level (α) was 0.05. The dual luciferase reporter gene experiment was performed by two independent sample t test. P<0.05 was considered statistically significant.

[0084] 2. Results

[0085] 2.1 Identification of successful modeling

[0086] Three days after modeling, all activities of the normal control group were normal, and the BBB score was 20 points. The lower limbs of the model group were weak, with a score of 2-4 points, which was statistically significant compared with the normal control group (P<0.01). This proves that the modeling was successful. The scores are shown in Table 1.

[0087] Table 1 BBB scores of rats in each group 3 days after modeling

[0088]

[0089] 2.2 Analysis results of differentially expressed gene profiles between normal control group rats and model group rats

[0090] The results were analyzed by group T test, and the fold change value (foldchange) greater than 1.5 or less than 0.6667 and P value less than 0.05 were used as the criteria for screening. 585 differentially expressed genes between the model group and the normal control group were obtained, among which factors related to cell apoptosis included Bax and cellular cysteine ​​protease 11 (Caspase 11).

[0091] 2.3 Screening of differentially expressed miRNAs in the serum of normal control group rats and model group rats

[0092] All differentially expressed miRNAs with intergroup fold change (FC) ≥ 1.5 and P ≤ 0.05 between the two groups were collected to establish a differentially expressed miRNA library. A total of 24 miRNAs were elevated in the model group relative to the normal control group, as shown in Table 2.

[0093] Table 2 Summary of miRNAs elevated in the model group relative to the normal control group

[0094]

[0095]

[0096] The bioinformatics websites TargetScan and miRWalk predicted 70 and 418 miRNAs regulating Bax, respectively. Then, 38 common differentially expressed miRNAs screened by the two methods were found. The differentially expressed miRNAs that can regulate Bax protein screened by the chip method of the present invention have a common miRNA, namely miR-495-3p. No miRNA that can regulate caspase 11 was screened.

[0097] 2.4 Western blot detection of Bax expression in spinal cord tissue

[0098] The results of Western blot detection of Bax expression level in spinal cord tissue are as follows Figure 2 The statistical results are shown in Figure 3 As shown, spinal cord injury in the model group rats caused high expression of Bax in the spinal cord tissue, and the abundance of Bax expression was increased compared with that in the normal control group.

[0099] 2.5 Apoptosis of spinal cord cells in rats with spinal cord injury

[0100] The results of flow cytometry were as follows Figure 4 As shown, the majority of cells in the spinal cord tissue of rats in the normal control group were distributed in the fourth quadrant (e.g. Figure 4 (shown in A), which are normal living cells; compared with the normal control group, the number of cells distributed in the second and third quadrants in the spinal cord tissue of rats in the model group increased significantly (as shown in Figure 4 (shown in B), indicating an increase in apoptotic or necrotic cells.

[0101] The statistical results of apoptotic cells are as follows Figure 5 As shown in the figure, the apoptosis rate of spinal cord cells in the model group was significantly higher than that in the normal control group (P<0.01).

[0102] 2.6 Bioinformatics detection and PCR experimental results

[0103] There are three miRNAs that regulate Bax detected by the miRDB website and the miRwalk website, namely miR-495-3p, miR-337-5p and miR-124-3p. Combined with the experimental results in 2.3, the present invention selects miR-495-3p for tracking research.

[0104] PCR results are as follows Figure 6 As shown, 3 days after modeling, the content of miR-495-3p in the spinal cord tissue of the model group was 0.677±0.183, which was significantly lower than that of the normal control group (1.110±0.122) (F=11.650, P=0.027).

[0105] 2.7 Results of dual luciferase reporter gene experiments

[0106] The results of the dual luciferase reporter gene experiment showed that the relative fluorescence activity of the Bax mutant was significantly higher than that of the Bax wild type (P<0.01), indicating that miR-495-3p and the Bax wild type can be well combined with each other and have a regulatory relationship. Figure 7 shown.

[0107] 2.8 Spinal cord neuron cell culture and identification

[0108] like Figure 8 As shown, the newly inoculated spinal cord neuron cells are scattered in a round shape, with uniform cytoplasm, transparent cell bodies, and halos around them; after 2 days, the processes become longer, showing obvious neuronal morphology.

[0109] Type III β-tubulin is a marker for neuronal dendrites, and DAPI is a fluorescent dye that binds to DNA. After DAPI staining and immunofluorescence β-ⅢTubulin antibody staining, the cell nucleus exhibits blue fluorescence (such as Fig. 9 The cytoplasm shows red fluorescence (as shown in A). Fig. 9 The combination of the two staining methods showed obvious characteristics of nerve cells (such as Fig. 9 (as shown in C).

[0110] 2.9 Effect of miR-495-3p on Bax expression in spinal cord cells

[0111] The results of Western blot detection of Bax expression in cultured spinal cord neurons are shown in Fig.10 The statistical results are shown in Fig.11 As shown, compared with the normal control group, Bax was highly expressed in the cells of the model group and miR-495-3p inhibitor group, while the expression level of Bax in the cells of the miR-495-3p mimics group was significantly downregulated compared with that in the model group.

[0112] 2.10 Detection results of Bax, Bcl-2, and Bcl-2 / Bax in cultured spinal cord neurons

[0113] The test results are shown in Table 3. It can be seen that the content of Bax in the spinal cord neurons of the spinal cord injury model group was significantly increased compared with the normal control group, and the difference was statistically significant (P<0.01). The results of the miR-495-3p inhibitor group and the model group were similar, while the miR-495-3p mimics group could reverse the phenomenon of significant increase in Bax content. Compared with the model group, miR-495-3pmimics significantly reduced the expression of Bax (P<0.01). Compared with the normal control group, the content of Bcl-2 in the spinal cord injury model group, miR-495-3pmimics group and miR-495-3p inhibitor group was significantly reduced, and there was no significant difference between the results of the three groups. The miR-495-3p mimics group significantly increased the ratio of Bcl-2 / Bax by reducing the expression of Bax (P<0.01).

[0114] Table 3 Contents of Bax and Bcl-2 in spinal cord neurons and the ratio of Bcl-2 / Bax

[0115]

[0116] Note: Compared with the normal control group, * is P<0.05, ** is P<0.01; compared with the model group, ▲ P < 0.05, ▲▲ P<0.01.

[0117] 2.11 Effect of miR-495-3p on apoptosis of spinal cord cells in rats with spinal cord injury

[0118] The results of flow cytometry were as follows Fig.12 As shown, most of the cells in the normal control group are in the fourth quadrant, which are normal living cells (such as Fig.12Compared with the normal control group, the number of cells distributed in the third and second quadrants in the model group and the miR-495-3p inhibitor group increased, corresponding to the increase in early and mid-late apoptotic or necrotic cells, respectively (as shown in Figure 2A). Fig.12 Compared with the model group, the number of cells in the third and second quadrants of the miR-495-3p mimics group decreased, and the apoptosis phenomenon was alleviated (as shown in Figure 2B and D). Fig.12 (as shown in C).

[0119] The statistical results of apoptotic cells are as follows Fig.13 As shown in the figure, the apoptosis rates of the model group and the miR-495-3p inhibitor group were significantly higher than those of the normal control group (P<0.01); there was no significant difference in the apoptosis rate of the miR-495-3p mimics group compared with the normal control group. The results showed that miR-495-3p mimics can inhibit the apoptosis of spinal cord cells.

[0120] 2.12 Effect of miR-495-3p on the recovery of spinal cord function in rats with spinal cord injury

[0121] The rats were divided into a normal control group, a model group, a miR-495-3p mimics group, and a miR-495-3p inhibitor group. The BBB scores of the rats were performed after 7 days of treatment, and the scoring results are shown in Table 4. The results showed that the miR-495-3p mimics group could restore the BBB score of muscle spasm after spinal cord injury, and the difference was statistically significant compared with the model control group (P<0.01), while the BBB score of the miR-495-3p inhibitor group was not statistically different from that of the model group.

[0122] Table 4 Effects of plasma exosomes enriched with miR-495-3p on functional recovery in rats with spinal cord injury

[0123]

[0124] Note: Compared with the normal control group, ★★ P<0.01; compared with the model group, ▲▲ P<0.01; compared with the miR-495-3pmimics group, ■■ P<0.01.

[0125] The above results indicate that miR-495-3p can be used to treat spinal cord injury, which is of great significance for the clinical treatment or drug development of spinal cord injury.

[0126] The research results of the present invention show that there is a regulatory relationship between miR-495-3p and Bax, and there is a miR-495-3p / Bcl-2 / Bax regulatory pathway in the body after spinal cord injury; by upregulating the level of miR-495-3p, the expression of Bax can be downregulated, and the expression ratio of Bcl-2 / Bax can be further adjusted, thereby regulating the apoptosis of spinal cord neuron cells and affecting spinal cord injury. Therefore, increasing the expression level of miR-495-3p can play a role in treating spinal cord injury, thereby providing a new pathway and method for the treatment of spinal cord injury.

[0127] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Application of miR-495-3p in the preparation of drugs for the treatment of spinal cord injury.

2. Application of miR-495-3p in the preparation of drugs for inhibiting neuronal cell apoptosis after spinal cord injury.

3. Application of miR-495-3p in the preparation of B-cell lymphoma-2-associated X protein regulators, It is characterized in that The miR-495-3p downregulates the expression level of B-cell lymphoma-associated X protein.

4. The use according to any one of claims 1 to 3, It is characterized in that The nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.

5. A drug for treating spinal cord injury, It is characterized in that Including miR-495-3p.

6. A drug for inhibiting neuronal apoptosis after spinal cord injury. It is characterized in that Including miR-495-3p.

7. The drug according to any one of claims 5 or 6, It is characterized in that The nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.

8. The drug according to claim 7, It is characterized in that Pharmaceutically acceptable excipients are also included.

9. A B-cell lymphoma-associated protein X regulator, It is characterized in that The invention comprises miR-495-3p; the miR-495-3p downregulates the expression level of B-cell lymphoma-associated X protein.

10. The regulator according to claim 9, It is characterized in that The nucleotide sequence of the miR-495-3p is 5'-AAACAAACAUGGUGCACUUCUU-3'.